Dana-Farber Cancer Institute

Physician Resources for Stem Cell Transplant and Cellular Therapies

    In this section

    We collaborate with referring providers to ensure that more patients can access the most advanced care and treatment available. Dana-Farber Brigham Cancer Center has a long history of utilizing cellular therapies to treat blood cancers and blood disorders. For over 50 years, we have performed more than 12,400 hematopoietic stem cell transplants—the original form of cellular therapy. We continue to offer patients the latest treatments, including CAR T-cell therapy, other genetically-modified T cells, and cancer vaccines.

    Explore our history, progress, and innovation in adult stem cell transplantation.

    Through partnering with you, we can help your patients receive their care closer to home, reducing the time and cost of care without sacrificing quality. Learn more about our unique approach, and how to refer your patients to our Stem Cell Transplantation and Cellular Therapies programs:

    Stem Cell Transplant Resources Cellular Therapies Resources

    Stem Cell Transplantation and Cellular Therapies Annual Symposium

    This annual education program is for physicians, nurses, social workers, and payors who care for patients with cancer who may be appropriate for cellular therapy treatment. The symposium features presentations and panel discussions about the rapidly emerging and evolving cellular therapies, with insight on eligibility, referral guidelines, and post-treatment management.

    Payer and Provider Webinar for Advancing Patients through Cellular Therapy Treatment

    This webinar from May 21, 2025, provides an update on navigating emerging and evolving cellular therapies, with a focus on which patients may be appropriate for cellular therapy treatment. It covers an overview of cellular therapy treatment options, expanding the role of cell therapies in multiple myeloma, updates on gene therapy at Dana-Farber, and best practices for working together to ensure patients receive timely access to necessary care.

    0:00 – Welcome, Introduction
    Kidest Mequanent, MHA
    Network Manager, Cell Therapies

    2:06 – Understanding Cellular Therapy Treatment Options: Autologous Stem Cell Transplant, CAR T-cell Therapy, and Bispecific Antibody Therapy 
    Caron Jacobson, MD, MMSc 
    Medical Director, Immune Effector Cell Therapy Program

    24:03 – Determining Cellular Therapy Treatment for Patients with Multiple Myeloma 
    Omar Nadeem, MD 
    Clinical Director, Myeloma Immune Effector Cell Therapy Program and Center for Early Detection and Interception of Blood Cancers

    42:35 – Update on Gene Therapy at Dana-Farber 
    Amar Kelkar, MD 
    Lead Faculty Clinician for Adult Gene Edited Stem Cell Transplant

    56:36 – Overall Payer Challenges from the Financial Perspective 
    Pat Kelley, BSN, RN 
    Associate Director, Clinical Service Authorizations

    Cell Manipulation Core Facility at Dana-Farber Cancer Institute

    The Connell and O’Reilly Families Cell Manipulation Core Facility (CMCF) at Dana-Farber Cancer Institute is a state-of-the-art academic GMP laboratory dedicated to the production of cellular therapies for cancer, in vitro gene therapy, and regenerative medicine applications. The CMCF lab is an experienced manufacturer of CAR T cells, cancer vaccines, dendritic cells, regulatory T cells, natural killer cells, cytotoxic T cells, genetically modified hematopoietic stem cells, induced pluripotent stem cells, limbal stem cells, mesenchymal stromal cells, and more. 

    Program Accreditations, Registrations, and Licenses

    • Foundation for the Accreditation of Cellular Therapy (FACT)
    • U.S. Food and Drug Administration
    • American Association of Blood Banks (AABB)
    • Centers for Medicare and Medicaid Services
    • The Joint Commission
    • NMDP

    Clinical and Research Affiliations

    • Member of the Center for International Blood and Marrow Transplant Research (CIBMTR)
    • Charter member of the Blood and Marrow Transplant Clinical Trials Network of the National Institutes of Health (BMT-CTN)
    • Member of the Alliance for Clinical Trials in Oncology (formerly CALGB)
    • Founding member of Dana-Farber/Harvard Cancer Center, designated a comprehensive cancer center by the National Cancer Institute

    Clinical Education Opportunities

    We offer observerships for physicians, mid-level practitioners, and nurses to shadow clinicians in the Hematologic Malignancies and Stem Cell Transplant departments. While observerships are overseen organizationally by Dana-Farber, curricula and scheduling are managed directly by each department. For hematologic malignancy and stem cell transplant observerships, email katie_kupferberg@dfci.harvard.edu.

    In addition, as a principal teaching affiliate of Harvard Medical School, we share advances in cancer research and treatment with the health care community through continuing medical education (CME) and continuing educational unit (CEU) courses. Learn more about education and training opportunities.

    Subscribe to Advances in Hematologic Malignancies

    This free biannual e-newsletter provides updates about Dana-Farber’s hematologic oncology research and care, current clinical trials, and upcoming CME programs.

    Subscribe